Review ArticleClinical Review

Management of Chronic Hepatitis B: An Overview of Practice Guidelines for Primary Care Providers

Steven-Huy Han and Tram T. Tran
The Journal of the American Board of Family Medicine November 2015, 28 (6) 822-837; DOI: https://doi.org/10.3122/jabfm.2015.06.140331

References

  1. 1.↵
    World Health Organization. Hepatitis B. Fact sheet no. 204. Updated 2015. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed September 18, 2015.
  2. 2.↵
    1. Lozano R,
    2. Naghavi M,
    3. Foreman K,
    4. et al
    . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Ioannou GN
    . Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011;154:319–28.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Hosaka T,
    2. Suzuki F,
    3. Kobayashi M,
    4. et al
    . Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98–107.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Zoutendijk R,
    2. Reijnders JG,
    3. Zoulim F,
    4. et al
    . Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013;62:760–5.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Wong GL,
    2. Chan HL,
    3. Mak CW,
    4. et al
    . Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537–47.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Lim YS,
    2. Han S,
    3. Heo NY,
    4. Shim JH,
    5. Lee HC,
    6. Suh DJ
    . Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014;147:152–61.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Wu CY,
    2. Lin JT,
    3. Ho HJ,
    4. et al
    . Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-a nationwide cohort study. Gastroenterology 2014;147:143–51.e5.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Gordon SC,
    2. Lamerato LE,
    3. Rupp LB,
    4. et al
    . Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014;12:885–93.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Lok AS,
    2. McMahon BJ
    . Chronic hepatitis B: update 2009. Hepatology 2009;50:661–2.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Liaw YF,
    2. Kao JH,
    3. Piratvisuth T,
    4. et al
    . Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531–61.
    OpenUrlCrossRefPubMed
  12. 12.↵
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–85.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Han SH,
    2. Jing W,
    3. Mena E,
    4. et al
    . Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy. J Med Econ 2012;15:1159–66.
    OpenUrlPubMed
  14. 14.↵
    1. Wu Y,
    2. Johnson KB,
    3. Roccaro H,
    4. et al
    . Poor adherence to AASLD guidelines for chronic hepatitis B management in a large academic medical center. Am J Gastroenterol 2014;109:867–75.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Burman BE,
    2. Mukhtar NA,
    3. Toy BC,
    4. et al
    . Hepatitis B management in Vulnerable populations: gaps in disease monitoring and opportunities for improved care. Dig Dis Sci 2013;59:46–56.
    OpenUrlPubMed
  16. 16.↵
    1. Juday T,
    2. Tang H,
    3. Harris M,
    4. Powers AZ,
    5. Kim E,
    6. Hanna GJ
    . Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. J Gen Intern Med 2011;26:239–44.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Ku KC,
    2. Li J,
    3. Ha NB,
    4. Martin M,
    5. Nguyen VG,
    6. Nguyen MH
    . Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics. Dig Dis Sci 2013;58:3626–33.
    OpenUrlPubMed
  18. 18.↵
    1. Upadhyaya N,
    2. Chang R,
    3. Davis C,
    4. Conti MC,
    5. Salinas-Garcia D,
    6. Tang H
    . Chronic hepatitis B: perceptions in Asian American communities and diagnosis and management practices among primary care physicians. Postgrad Med 2010;122:165–75.
    OpenUrlPubMed
  19. 19.↵
    1. Les I,
    2. Garcia-Martinez R,
    3. Cordoba J,
    4. Quintana M,
    5. Esteban R,
    6. Buti M
    . Current trends in chronic hepatitis B management: results of a questionnaire. Eur J Gastroenterol Hepatol 2009;21:1177–83.
    OpenUrlPubMed
  20. 20.↵
    1. Ning LH,
    2. Hao J,
    3. Liao ZL,
    4. Zhou YY,
    5. Guo H,
    6. Zhao XY
    . A survey on the current trends in the management of hepatitis B in China. Eur J Gastroenterol Hepatol 2012;24:884–9.
    OpenUrlPubMed
  21. 21.↵
    1. Liang TJ
    . Hepatitis B: the virus and disease. Hepatology 2009;49:S13–S21.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Liaw YF
    . Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009;29(Suppl 1):100–7.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Kwon H,
    2. Lok AS
    . Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011;8:275–84.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Chen CJ,
    2. Yang HI,
    3. Su J,
    4. et al
    . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Chan HL,
    2. Tse CH,
    3. Mo F,
    4. et al
    . High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008;26:177–82.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Chen G,
    2. Lin W,
    3. Shen F,
    4. Iloeje UH,
    5. London WT,
    6. Evans AA
    . Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797–803.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Zaman A,
    2. Rosen HR,
    3. Ingram K,
    4. Corless CL,
    5. Oh E,
    6. Smith K
    . Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007;120:280.e9–14.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Naveau S,
    2. Gaude G,
    3. Asnacios A,
    4. et al
    . Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009;49:97–105.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Liaw YF
    . HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425–33.
    OpenUrlPubMed
  30. 30.↵
    1. Chu CM,
    2. Liaw YF
    . Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010;15:133–43.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Chen YC,
    2. Chu CM,
    3. Liaw YF
    . Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010;51:435–44.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Funk ML,
    2. Rosenberg DM,
    3. Lok AS
    . World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52–61.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Mitchell AE,
    2. Colvin HM,
    3. Palmer Beasley R
    . Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010;51:729–33.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Hatzakis A,
    2. Wait S,
    3. Bruix J,
    4. et al
    . The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011;18(Suppl 1):1–16.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. LeFevre ML
    ; U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:58–66.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Hu KQ,
    2. Pan CQ,
    3. Goodwin D
    . Barriers to screening for hepatitis B virus infection in Asian Americans. Dig Dis Sci 2011;56:3163–71.
    OpenUrlPubMed
  37. 37.↵
    1. Averhoff F
    . Yellowbook. Chapter 3: Infectious diseases related to travel. July 10, 2015. Atlanta: Centers for Disease Control and Prevention. Available from: http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/hepatitis-b. Accessed September 18, 2015.
  38. 38.↵
    1. Marcellin P,
    2. Gane E,
    3. Buti M,
    4. et al
    . Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2012;38:468–75.
    OpenUrl
  39. 39.↵
    1. Shim JH,
    2. Lee HC,
    3. Kim KM,
    4. et al
    . Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176–82.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Schiff ER,
    2. Lee SS,
    3. Chao YC,
    4. et al
    . Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9:274–6.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Han K-H,
    2. Kim DY
    . Chronic HBV infection with persistently normal ALT b. not to treat. Hepatol Int 2008;2:185–9.
    OpenUrl
  42. 42.↵
    1. Chan HL,
    2. Chan CK,
    3. Hui AJ,
    4. et al
    . Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 2014;146:1240–8.
    OpenUrlCrossRefPubMed
  43. 43.
    1. Comanor L,
    2. Minor J,
    3. Conjeevaram HS,
    4. et al
    . Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. J Viral Hepat 2001;8:139–47.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Yuen MF,
    2. Seto WK,
    3. Fung J,
    4. Wong DK,
    5. Yuen JC,
    6. Lai CL
    . Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011;106:1264–71.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Liaw YF
    . Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011;53:2121–9.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Huo TI,
    2. Wu JC,
    3. Lee PC,
    4. et al
    . Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998;28:231–6.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Wong PY,
    2. Xia V,
    3. Imagawa DK,
    4. Hoefs J,
    5. Hu KQ
    . Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health 2011;13:842–8.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Tseng TC,
    2. Liu CJ,
    3. Yang HC,
    4. et al
    . High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140–9.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    1. Tenney DJ,
    2. Rose RE,
    3. Baldick CJ,
    4. et al
    . Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503–14.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Heo J,
    2. Ahn SH,
    3. Kweon YO,
    4. et al
    . Entecavir + adefovir versus lamivudine + adefovir or entecavir alone in lamivudine-resistant chronic hepatitis B: 96-week data from the DEFINE study. J Clin Exp Hepatol 2013;3(Suppl):S60.
    OpenUrl
  51. 51.↵
    1. Jablkowski M,
    2. Diculescu M,
    3. Janssen HLA,
    4. et al
    . The safety and efficacy of entecavir and tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. Hepatology 2013;58:711A (abstract 1044).
    OpenUrl
  52. 52.↵
    1. Zoutendijk R,
    2. Reijnders JG,
    3. Brown A,
    4. et al
    . Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011;54:443–51.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Luo J,
    2. Li X,
    3. Wu Y,
    4. et al
    . Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life. Int J Med Sci 2013;10:427–33.
    OpenUrlPubMed
  54. 54.↵
    1. Ko SY,
    2. Choe WH,
    3. Kwon SY,
    4. et al
    . Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy. Scand J Gastroenterol 2012;47:1362–7.
    OpenUrlPubMed
  55. 55.↵
    1. Zoulim F
    . Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004;64:1–15.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    1. Shouval D,
    2. Lai CL,
    3. Chang TT,
    4. et al
    . Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50:289–95.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    1. Reijnders JG,
    2. Perquin MJ,
    3. Zhang N,
    4. Hansen BE,
    5. Janssen HL
    . Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139:491–8.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.↵
    1. Petersen J,
    2. Buggisch P,
    3. Stoehr A,
    4. et al
    . Stopping long-term nucleos(t)ide analogue therapy before HBsAg loss or seroconversion in HBeAg negative CHB patients: experience from five referral centers in Germany. Hepatology 2011;54:1033A (abstract 1417).
    OpenUrl
  59. 59.↵
    1. Hadziyannis SJ,
    2. Sevastianos V,
    3. Rapti I,
    4. Vassilopoulos D,
    5. Hadziyannis E
    . Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012;143:629–36.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Song MJ,
    2. Song do S,
    3. Kim HY,
    4. et al
    . Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012;18:6277–83.
    OpenUrlPubMed
  61. 61.↵
    1. Petersen J,
    2. Buggisch P,
    3. Hinrichsen H,
    4. et al
    . Stopping long-term nucleos(t)ide analogue therapy before HbsAg loss in HbeAg negative CHB patients: follow-up of long-term responders. J Hepatol 2013;58:S313 (abstract 770).
    OpenUrl
  62. 62.↵
    1. Dusheiko G
    . Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int 2013;33(Suppl 1):137–50.
    OpenUrl
  63. 63.↵
    1. Chan HL,
    2. Wong GL,
    3. Choi PC,
    4. et al
    . Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009;16:36–44.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Wong GL,
    2. Wong VW,
    3. Choi PC,
    4. et al
    . Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol 2008;6:1027–35.
    OpenUrlCrossRefPubMedWeb of Science
  65. 65.↵
    1. Fattovich G,
    2. Bortolotti F,
    3. Donato F
    . Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–52.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    1. Papatheodoridis GV,
    2. Chan HL,
    3. Hansen BE,
    4. Janssen HL,
    5. Lampertico P
    . Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015;62:956–67.
    OpenUrlPubMed
  67. 67.↵
    1. Bruix J,
    2. Sherman M
    . Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    1. Wong VW,
    2. Chan SL,
    3. Mo F,
    4. et al
    . Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660–5.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    1. Yuen MF,
    2. Tanaka Y,
    3. Fong DY,
    4. et al
    . Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80–8.
    OpenUrlCrossRefPubMedWeb of Science
  70. 70.↵
    1. Yang HI,
    2. Yuen MF,
    3. Chan HL,
    4. et al
    . Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568–74.
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.↵
    1. Papatheodoridis G,
    2. Dalekos G,
    3. Sypsa V,
    4. et al
    . PAGE-B: risk score for hepatocellular carcinoma (HCC) development in Caucasian chronic hepatitis B (CHB) patients receiving entecavir (ETV) or tenofovir (TDF). J Hepatol 2014;60:S435 (abstract P1075).
    OpenUrl
  72. 72.↵
    1. Block TM,
    2. Gish R,
    3. Guo H,
    4. et al
    . Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res 2013;98:27–34.
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Matsuzaki T,
    2. Ichikawa T,
    3. Otani M,
    4. et al
    . The significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of HBV re-infection after liver transplantation. J Gastroenterol Hepatol 2013;28:1217–22.
    OpenUrlPubMed
  74. 74.↵
    1. Wong DK,
    2. Seto WK,
    3. Fung J,
    4. et al
    . Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 2013;11:1004–10.
    OpenUrlCrossRefPubMed
  75. 75.↵
    1. Werle-Lapostolle B,
    2. Bowden S,
    3. Locarnini S,
    4. et al
    . Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750–8.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Bowden S,
    2. Locarnini S,
    3. Chang TT,
    4. et al
    . Impact of entecavir versus lamivudine on hepatic HBV covalently closed-circular DNA and total hepatic HBV DNA in nucleoside-naïve HBeAg positive chronic hepatitis B patients. J Hepatol 2013;58:S308 (abstract 759).
    OpenUrl
  77. 77.↵
    1. Takkenberg B,
    2. Terpstra V,
    3. Zaaijer H,
    4. et al
    . Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol 2011;26:1527–35.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Cai D,
    2. Mills C,
    3. Yu W,
    4. et al
    . Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012;56:4277–88.
    OpenUrlAbstract/FREE Full Text
  79. 79.↵
    1. Chan HL,
    2. Thompson A,
    3. Martinot-Peignoux M,
    4. et al
    . Hepatitis B surface antigen quantification: why and how to use it in 2011–a core group report. J Hepatol 2011;55:1121–31.
    OpenUrlCrossRefPubMedWeb of Science
  80. 80.↵
    1. Lok AS,
    2. Trinh H,
    3. Carosi G,
    4. et al
    . Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012;143:619–28.
    OpenUrlCrossRefPubMed
  81. 81.↵
    1. Sonneveld MJ,
    2. van Vuuren AJ,
    3. Verhey E,
    4. et al
    . Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance: first results from a global randomized trial (ARES study). Hepatology 2012;56(Suppl S1):199A (abstract 19).
    OpenUrl
  82. 82.↵
    1. Ning Q,
    2. Han M,
    3. Sun Y,
    4. et al
    . New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a induces HBeAg seroconversion/HBsAg clearance in patients with HBeAg-positive chronic hepatitis B. Hepatology 2012;56(Suppl S1):300A (abstract 216).
    OpenUrlWeb of Science
  83. 83.↵
    1. Michel ML,
    2. Mancini-Bourgine M
    . Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 2005;34(Suppl 1):S108–14.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords